Dr. Reddy’s Eschews M&As In Quest To Be Lead Generics Maker In 2013
This article was originally published in PharmAsia News
Dr. Reddy’s Laboratories, which has largely eschewed large acquisitions, nonetheless expects to make its mark on the global market, becoming India’s largest maker of generics drugs by surpassing Ranbaxy Laboratories next year.
You may also be interested in...
The $9.7bn acquisition hinges on the small interfering RNA inclisiran, but an ongoing cardiovascular outcomes trial, manufacturing hurdles, and reimbursement challenges provide subjects for concern.
US congressional leaders and medtech industry advocacy group AdvaMed are giving their full-throated endorsement to a US-Mexico-Canada (USMCA) trade agreement announced by the US Trade Representative's Office on 10 December. See what AdvaMed's president and CEO, Scott Whitaker, said about it in a statement here.
FDA seems poised to approve the drug for the orphan eye disease called TED, but remains concerned about labeling for some adverse events.